News

Price Chopper revises, expands coupon policy

BY Antoinette Alexander

SCHNECTADY, N.Y. — Price Chopper Supermarkets, a Golub Corp. company, is revising and expanding its coupon policy in response to ever-evolving couponing trends.

The updated policy, which will go into effect in conjunction with the chain’s weekly ad on Sept. 14, includes changes and clarifications, such as:

  • Price Chopper will match competitive paper coupons for store brands with its own Price Chopper brand products of the same size and weight (Price Chopper has been matching paper coupons for store brands for several months now, but given their relative newness to the marketplace, they were not included in the last iteration of our coupon policy.)
  • Price Chopper has expanded its AdvantEdge e-coupon offerings, which can be loaded to a customer’s AdvantEdge card through pricechopper.com or the Price Chopper mobile app
  • Price Chopper will accept one paper competitor “dollars off a category” coupon from other supermarkets and mass retailers, the value of which may not exceed 50% of the order (Price Chopper has been matching such paper competitor “dollars off a category” coupons for several months now, but given their relative newness to the marketplace, they were not included in the last version of the company’s coupon policy.)

“This newest iteration of our coupon policy builds on an already robust savings platform that honors double coupons up to and including 99 cents, matches competitors’ coupons and offers cumulative fuel and bonus fuel rewards based on whole order and single item purchases. Some of the revisions formalize the honoring of coupons we’ve been accepting for some time and others help to clarify our policies for ease of use,” said Mona Golub, Price Chopper’s VP of public relations and consumer services. “And, the addition of store brand product coupons in the new policy simply gives customers the opportunity to save more money while enjoying the added value of our high quality Price Chopper brand.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Target app to integrate with new Apple Pay

BY Antoinette Alexander

MINNEAPOLIS — Target has announced that it is integrating with the new Apple Pay mobile payments service so shoppers can pay using the Target app from iOS.

“We know mobile is becoming the front door to Target, and we’re focused on creating the best possible mobile experiences for our guests,” stated Jason Goldberger, SVP of Target.com and mobile, in the company’s “A Bullseye View” newsletter. “We’re thrilled to support Apple Pay to streamline how our guests pay in the Target app – this absolutely makes purchasing from Target’s mobile app easier than ever.”

The new Apple Pay is a mobile payments service that will provide an easy way to make purchases from iPhone 6 or iPhone 6 Plus. Shoppers using the Target app from iOS can make purchases with one touch using Touch ID.

Apple Pay will be available in the Target iPhone app in October with a free update to iOS 8, the retailer stated.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

PhRMA: 44 medicines and vaccines for HIV/AIDS treatment and prevention in development

BY Michael Johnsen

 

WASHINGTON — America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America issued Wednesday. 
 
A second report, a PhRMA-sponsored white paper by Boston Healthcare Associates, “The Value of Innovation in HIV/AIDS Therapy” highlights the progress in HIV/AIDS treatment and its impact on patients with the disease. 
 
Both reports are being released in conjunction with PhRMA’s 2014 Research & Hope Awards, which will honor researchers and patient advocates for their role in improving HIV/AIDS research and care.
 
“Over the past 35 years, HIV/AIDS has gone from a death sentence to a chronic, manageable disease thanks in large part to advances in biopharmaceutical research,” stated PhRMA president and CEO John Castellani. “Despite the progress that has been made, researchers are continuing the fight against HIV/AIDS and, with more than 40 medicines in the pipeline, there is more hope than ever that a cure can be achieved.”
 
Currently, biopharmaceutical companies are focused on improved treatment regimens, more effective therapies and preventive vaccines that are either in clinical trials or awaiting review by the Food and Drug Administration. The 44 medicines and vaccines in the development pipeline include 25 antivirals, 16 vaccines and three cell/gene therapies. 
 
Today, there are 94 active clinical trials for HIV medicines and vaccines in the United States. Of those, 43 have not yet started recruiting patients or have recently begun seeking participants. Therapies being investigated involve attachment inhibitors, gene modification and inducing T-cell responses, among others. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?